Full Video Abstract: Evidence for Oral Semaglutide in Type 2 Diabetes
This infographic to The American Journal of Managed Care® supplement, "The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective," describes key managed care information on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of type 2 diabetes in the United States, and appraises the clinical evidence for the first oral GLP-1RA, oral semaglutide.
Click
Articles in this issue
almost 5 years ago
Article
The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspectivealmost 5 years ago
Article
Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed CareNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Overcoming Weight Bias in Health Care Systems
September 15th 2025